IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections | Zendy

Joseph S. Solomkin | Zendy; Jānis Gardovskis | Zendy; Kenneth Lawrence | Zendy; Philippe Montravers | Zendy; Angie Sway | Zendy; David C. Evans | Zendy; Larry Tsai | Zendy

Open Access

IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections

Author(s) -

Joseph S. Solomkin,

Jānis Gardovskis,

Kenneth Lawrence,

Philippe Montravers,

Angie Sway,

David C. Evans,

Larry Tsai

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy1029

Subject(s) - medicine , meropenem , clinical endpoint , population , adverse effect , carbapenem , confidence interval , randomized controlled trial , clinical trial , surgery , antibiotics , antibiotic resistance , microbiology and biotechnology , biology , environmental health

Increasing antimicrobial resistance among pathogens that cause complicated intraabdominal infections (cIAIs) supports the development of new antimicrobials. Eravacycline, a novel member of the fluorocycline family, is active against multidrug-resistant bacteria including extended-spectrum β-lactamase (ESBL) and carbapenem-resistant Enterobacteriaceae.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research